For research use only.

Catalog No.S7008 Synonyms: AG 1879,AGL 1879

76 publications

PP2 Chemical Structure

CAS No. 172889-27-9

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 180 In stock
USD 70 In stock
USD 147 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PP2 has been cited by 76 publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
LCK [1]
(Cell-free assay)
Fyn [1]
(Cell-free assay)
4 nM 5 nM
In vitro

PP2 inhibits Src by binding to an area of the molecule that does not overlap with the ATP binding domain. [2] PP2 (20 μM) induces 40-50% growth inhibition of HT29 cells, this concentration reduces the Src activity as early as 1 hour and maintains a 35% inhibition of Src activity for 2 days. PP2 (100 mM) decreases the Src activity of HT29 cells in a dose-dependent manner. PP2 (1 mM-100 mM) causes a dose-dependent growth inhibition of human colon cancer cells (HT29, SW480, and PMCO1), liver cancer cells (PLC/PRF/5, KYN-2, Li7, and HepG2), and breast cancer cells (MCF-7, MDA-MB-468, and BT-474). PP2 (20 μM) significantly increases aggregation in most of the cancer cells (HT29, SW480, PMCO1, PLC/PRF/5, KYN-2, Li7, MCF-7, and MDA-MB-468) in E-cadherin dependent manner. PP2 (20 μM) enhances E-cadherin expression and also strongly increases E-cadherin’s association with the actin cytoskeleton in cancer cells. PP2 (20 μM) increases the expression of α-catenin, β-catenin, and γ-catenin in HT29 cells, whereas in PLC/PRF/5 and MCF-7 cells, the total protein level of α-catenin does not change, but the levels of β- catenin and γ-catenin increases slightly. [3] PP2 inhibits proliferation of two cervical cancer cells (HeLa and SiHa) in a time- and dose-dependent manner. PP2 (10 μM) down-regulates pSrc-Y416, pEGFR-Y845, and -Y1173 expression levels in HeLa and SiHa cells. PP2 (10 μM) could modulate cell cycle arrest by up-regulating p21(Cip1) and p27(Kip1) in both HeLa and SiHa cells and down-regulating expression of cyclin A, and cyclin dependent kinase-2, -4 (Cdk-2, -4) in HeLa and of cyclin B and Cdk-2 in SiHa. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 MkC2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4SxOmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjBzIN88UU4> M2e4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N|c1Lz5{OEixOFM4PDxxYU6=
T-cells MmnUSpVv[3Srb36gZZN{[Xl? MorvTY5pcWKrdHnvckBw\iCjZHjld4lwdiCtaX7hd4UhcW5iaIXtZY4hXCClZXzsd{whUUN3MDC9JFAvPiEQvF2u NITM[W49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O|M3Oyd-MUiwO|c{PjN:L3G+
T-cells M1iwbWZ2dmO2aX;uJIF{e2G7 NWDPcWE6UW6qaXLpeIlwdiCxZjD0fZJwe2mwZTDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iVDDj[YxteyxiSVO1NEA:KDBwNjFOwG0v NWfHe|FzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiwO|c{PjNpPkG4NFc4OzZ|PD;hQi=>
SH-SY5Y M{\HOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M{PQbFczKGi{cx?= NIDld3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPIMXN[PVliY3XscJMh[XO|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgO|IhcHK|IHL5JHhVXCCjc4PhfUwhUUN3MDC9JFYvOSEQvF2u NEjrZW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUi1OlE2PSd-MkG4OVYyPTV:L3G+
Saos2 Mn\yR5l1d3SxeHnjbZR6KGG|c3H5 NXXibmNbPDhiaILz NGfaWWREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBU[W:|MjDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hQC5yNzFOwG0v MkLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{KwO|AoRjJ|OUOyNFcxRC:jPh?=
SaOS2 NYW2dIJbSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NGfNUpVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPhU3MzKGOnbHzzJIF{e2W|c3XkJIF{KGOnbHz1cIFzKH[rYXLpcIl1gSxiSVO1NEA:KDhwMTFOwG0v MlLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd7Mkm3PVIoRjF5OUK5O|kzRC:jPh?=
A431 MoX4SpVv[3Srb36gZZN{[Xl? Ml3zTY5pcWKrdH;yfUBm\m[nY4Sgc44heGixc4Doc{1UemNxbn;udIhwe3CqbzDh[pRmeiCHR1[gLFExOCC3TTmgd5RqdXWuYYTpc44hd2ZiQUSzNUBk\WyuczCoNlEqNCCLQ{WwJF0hOTdizszNMi=> M4frPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlQzLz5zNUGwPVY1OjxxYU6=
MEG01 M3i1cmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnvIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPRVewNUBk\WyuczygTWM2OCB;IEG3JO69VS5? M2jRfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MkW3OVE{Lz5zOEK1O|UyOzxxYU6=
A431 MkLLSpVv[3Srb36gZZN{[Xl? M{nvZmlvcGmkaYTvdpkh\W[oZXP0JI9vKHCqb4PwbI8uW3KlIDjUfZI1OTZrIHHmeIVzKEWJRjCoNVAxKHWPKTDzeIlufWyjdHnvckBw\iCDNEOxJINmdGy|IDizPEktKEmFNUCgQUAzOiEQvF2u MmruQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVzMEm2OFIoRjF3MUC5OlQzRC:jPh?=
K562 MlWyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mmj4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|LDDJR|UxKD1iMkWg{txONg>? MnL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NUe1NVMoRjF6MkW3OVE{RC:jPh?=
A431 M1rFb2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYDU[ZN1\WRiZn;yJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczygTWM2OCB;IEOyJO69VS5? M3zaPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3MUC5OlQzLz5zNUGwPVY1OjxxYU6=
A431 NIfWZmlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUHNfZhWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBCPDNzIHPlcIx{NCCLQ{WwJF0hOzJwMjFOwG0v MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjVyOUW3N{c,OTZ3MEm1O|M9N2F-
KU812 NHvpOYRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M2LxfmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS2W4NVIh[2WubIOsJGlEPTBiPTC0OUDPxE1w Ml60QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NUe1NVMoRjF6MkW3OVE{RC:jPh?=
A431 NUHieYl2TnWwY4Tpc44h[XO|YYm= NVnqTXBrOTBidV2= M2rtWGlvcGmkaYTpc44hd2ZiU4LjJIF2fG:yaH;zdIhwenmuYYTpc44hd2ZiWUSxPUBqdiCDNEOxJINmdGy|IHH0JFExKHWP MmXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ3MEm1O|MoRjF4NUC5OVc{RC:jPh?=
8701-BC NXz5cmhFWHKxYYDvdJRwfGmlIHHzd4F6 MYCxNEB2VQ>? Mnr2VJJw[XCxcITveIlkKGGldHn2bZR6KGGpYXnud5QhQDdyMT3CR{Bk\WyuczDheEAyOCC3TTDifUBRSVKSIHHzd4F6 MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjVyOUW3N{c,OTZ3MEm1O|M9N2F-

... Click to View More Cell Line Experimental Data

Methods Test Index PMID
Western blot
p-PI3K / PI3K / p-AKT / AKT / Bcl-2 / Caspase-3 ; 

PubMed: 30250573     

Protein expression of the PI3K/Akt/Bcl-2/caspase-3 signaling pathway members in A549 cells treated with various concentrations of PP2.

p-Src / Src / p-MAPK / MAPK ; 

PubMed: 23704208     

MCF-7:5C cells were treated with vehicle (0.1% DMSO) and PP2 (5×10−6mol/L) for different durations. Phosphorylated c-Src, MAPK, and Akt were detected by immunoblotting. Total c-Src, MAPK, and Akt were used for loading controls. 

30250573 23704208

PubMed: 18566211     

Immunofluorescence staining of β-catenin (green) of PP2 and vehicle-treated PC3 cells. Propidium iodide stains the nucleus (red). Bar represents 15 μm.

FAK / p-FAK ; 

PubMed: 17927818     

PP2 promotes cell rounding and cortical actin formation. Primary mouse chondrocytes were incubated for 24 hours with dimethyl sulphoxide (DMSO) or the Src inhibitor PP2 (10 μmol/l), and cells were stained with antibodies against total focal adhesion kinase (FAK) or FAK phosphorylated on residue tyrosine 397 (green), rhodamine-phalloidin (red) and DAPI (blue). In the presence of DMSO, total and phosphorylated actin localized to focal adhesions at the end of stress fibres. In cells treated with PP2, total FAK acquired a diffuse cytosolic staining, whereas the signal for phosphorylated FAK was greatly reduced (scale bar: 2 μm).

18566211 17927818
In vivo PP2 (5 mg/kg/day) induces some slowing in the growth rate of the primary tumors relative to the control treated with vehicle in SCID mice inoculated HT29 cells in the spleen. PP2 (5 mg/kg/day) induces some slowing in the growth rate of the primary tumors relative to the control treated with vehicle in SCID mice inoculated HT29 cells in the spleen. PP2 (5 mg/kg/day) significantly reduces the relative liver weight and liver metastasis volume compared with the controls in SCID mice inoculated HT29 cells in the spleen. [3] PP2 (1.5 mg/kg i.p.) treated rats show approximately 50% reduction of infarct size on T2-weighted MRI and in TTC staining compared with controls in rats with focal ischemic brain injury. PP2 (1.5 mg/kg i.p.) results in better the neurological score than controls in rats with focal ischemic brain injury. [5]


Kinase Assay:[1]
- Collapse

Immune complex enzyme assays:

The acid-treated enolase is diluted 1:20 with 1× PBS before aliquoting 100 mL/well into a Nunc 96-well high protein binding assay plate. Assay wells are then aspirated; blocked with 0.5% bovine serum, 1× PBS for 1 h at 37 ℃;and then washed five times with 300 mL of 1× PBS/well. The source of Lck is either LSTRA cells or Lck expressed in HeLa cells using a vaccinia expression system. FynT is expressed in HeLa cells using the vaccinia system. Cells (12.5× 106/mL) are lysed in lysis buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, and 23 trypsin inhibitory units/mL aprotinin), and the lysates are clarified by centrifugation at 14,000 cpm for 15 min at 4 ℃ in an Eppendorf tube. The clarified lysates are then incubated with the appropriate anti-kinase antibody at 10 μg/mL for 2 h at 4 ℃. Protein A-Sepharose beads are added to the antibody/lysate mixture at 250 μL/mL and allowed to incubate for 30 min at 4 ℃. The beads are then washed twice in 1 mL of lysis buffer and twice in 1 mL of kinase buffer (25 mM HEPES, 3 mM MnCl2, 5mM MgCl2, and 100 μM sodium orthovanadate) and resuspended to 50% (w/v) in kinase buffer. Twenty-five microliters of the bead suspension is added to each well of the enolase-coated 96-well high protein binding plate together with an appropriate concentration of compound and [γ-32P]ATP (25 μL/well of a 200 μCi/mL solution in kinase buffer). After incubation for 20 min at 20 ℃, 60 μLl of boiling 2× solubilization buffer containing 10 mM ATP is added to the assay wells to terminate the reactions. Thirty microliters of the samples is removed from the wells, boiled for 5 min, and run on a 7.5% SDS-polyacrylamide gel. The gels are subsequently dried and exposed to Kodak X-AR film. For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical density of the major substrate band, enolase p46, is determined. In companion experiments for measuring the activity of compounds against Lck, the assay plate is washed with two wash cycles on a Skatron harvester using 50 mM EDTA, 1 mM ATP. Scintillation fluid (100 μL) is then added to the wells, and 32P incorporation is measured using a micro-β-counter.
Cell Research:[3]
- Collapse
  • Cell lines: HT29, SW480, PMCO1, PLC/PRF/5, KYN-2, Li7, HepG2, MCF-7, MDA-MB-468 and BT-474 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 2 days
  • Method: Cell viability is determined using an in vitro toxicology assay kit following the manufacturer’s instructions. Cells are seeded in 96-well plates at day 0. Starting at day 1, cells are treated for 2 days with each of a series of increasing concentrations of PP2 (1 μM, 10 μM, and 100 μM). At the end of this period, cell proliferation is evaluated by a colorimetric assay based on the cleavage of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide by mitochondria dehydrogenase in viable cells, leading to formazan formation. This experiment is repeated three times with 10 determinations/tested concentration.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: SCID mice inoculated HT29 cells in the spleen
  • Dosages: 5 mg/kg/day
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 60 mg/mL (198.82 mM)
Ethanol 2 mg/mL (6.62 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+corn oil
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 301.77


CAS No. 172889-27-9
Storage powder
in solvent
Synonyms AG 1879,AGL 1879
Smiles CC(C)(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)Cl)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03842371 Not yet recruiting Other: Metabolic level of BCAAs in monocytes and macrophages Sepsis Syndrome West China Hospital February 11 2019 --
NCT02407626 Terminated Drug: Propofol|Drug: Sevoflurane Myocardial Ischemia Triemli Hospital|University of Alberta September 2015 Not Applicable
NCT02315287 Recruiting Drug: Pioglitazone|Drug: Lobeglitazone Type 2 Diabetes Seoul National University Bundang Hospital September 2014 Phase 4
NCT02036554 Unknown status Drug: Everolimus|Drug: Tacrolimus|Drug: Mycophenolic acid Kidney; Complications Allograft Seoul St. Mary''s Hospital|Novartis March 2013 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please suggest me the in vivo details about the dilution to reduce the amount of DMSO to 1 to 5%?

  • Answer:

    For in vivo study, we recommend to use 4% DMSO +Corn oil up to 2.5 mg/ml.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy PP2 | PP2 supplier | purchase PP2 | PP2 cost | PP2 manufacturer | order PP2 | PP2 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID